While there's no clear news of what just happened on Kharg Island, U.S. Central Command took to X to say that attacks are happening while Iran's embassy in Zimbabwe, a frequent commenter during the ...

AC Immune amended its collaboration agreement with Eli Lilly, extending development of potential treatments for Alzheimer's disease and other neurodegenerative diseases. The Swiss biopharmaceutical ...

Axios reporter Barak Ravid, who's well-connected in the White House, said on X that it was the U.S. military that conducted strikes on military targets on Kharg Island, citing a U.S. official.

Investors are now faced with the best opportunity in decades to buy beaten-down tech stocks, say Goldman Sachs strategists.

For five years now, the Fed has missed its 2% inflation target and it’s quite clear to strategist Dimitris Valatsas that the ...

And let's move back the other way. U.S. stock futures edged lower and crude began to rise as Iranian media report that the key Kharg Island was struck. Kharg Island handles approximately 90% of Iran’s ...

Climb Bio has won the Food and Drug Administration's fast-track designation for its proposed budoprutug treatment for the rare kidney disease primary membranous nephropathy, or pMN. The FDA's ...

Shares of health and insurance companies rose after the Trump administration said it will raise payments to Medicare insurers by 2.48% next year.

The presentation that will be reviewed during the conference call will be available on AB's Investor Relations website shortly after the release of our First Quarter 2026 financial and operating ...

Attacks on Saudi Arabia's eastern industrial hub of Jubail triggered a fire at facilities operated by Saudi Basic Industries Corp., intensifying geopolitical tensions across the Gulf and heightening ...

There's nothing concrete to explain the market's turn in equities and oil futures, though there's at least one positive comment about the possibility of a deal, coming from Iran's ambassador to ...

Shares of Organogenesis Holdings were higher after the company said its product for non-healing diabetic foot ulcers met its primary endpoint in a recent trial. The stock rose 30%, to $2.91, in ...